Cargando…

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

Receptor‐interacting protein kinase 1 (RIPK1), a regulator of inflammation and cell death, is a potential therapeutic target in immune‐mediated inflammatory diseases (IMIDs). The objective of this phase IIa multicenter, randomized, double‐blind, placebo‐controlled study was to evaluate safety, toler...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weisel, Kathleen, Berger, Scott, Papp, Kim, Maari, Catherine, Krueger, James G., Scott, Nicola, Tompson, Debra, Wang, Susanne, Simeoni, Monica, Bertin, John, Peter Tak, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540322/ https://www.ncbi.nlm.nih.gov/pubmed/32301501 http://dx.doi.org/10.1002/cpt.1852

Ejemplares similares

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis
por: Weisel, Kathleen, et al.
Publicado: (2021)

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2
por: Wagner, Roland N., et al.
Publicado: (2015)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

RIPK1 downregulation enhances neutrophil extracellular traps in psoriasis
por: Meng, Xinyu, et al.
Publicado: (2022)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)

Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis
por: Zhang, Xixi, et al.
Publicado: (2019)

Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation
por: Takiishi, Tatiana, et al.
Publicado: (2023)

Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death
por: Moriwaki, K, et al.
Publicado: (2015)

Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2
por: Annibaldi, Alessandro, et al.
Publicado: (2018)

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
por: Tompson, Debra J., et al.
Publicado: (2021)

The Role of RIPK1 and RIPK3 in Cardiovascular Disease
por: DeRoo, Elise, et al.
Publicado: (2020)

Discovery of a cooperative mode of inhibiting RIPK1 kinase
por: Meng, Huyan, et al.
Publicado: (2021)

Targeting RIPK1 kinase for modulating inflammation in human diseases
por: Li, Wanjin, et al.
Publicado: (2023)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
por: Mifflin, Lauren, et al.
Publicado: (2020)

Ripk1 and haematopoiesis: a case for LUBAC and Ripk3
por: Annibaldi, Alessandro, et al.
Publicado: (2018)

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
por: Tompson, Debra, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Caspase-8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3 regulate retinoic acid-induced cell differentiation and necroptosis
por: Someda, Masataka, et al.
Publicado: (2019)

RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function
por: Hänggi, Kay, et al.
Publicado: (2017)

RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense
por: Peterson, Lance W., et al.
Publicado: (2017)

Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis
por: Remijsen, Q, et al.
Publicado: (2014)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8
por: Imanishi, Takayuki, et al.
Publicado: (2023)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer
por: Lin, Penghang, et al.
Publicado: (2023)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1
por: Moujalled, D M, et al.
Publicado: (2013)

Identification of MYC as an antinecroptotic protein that stifles RIPK1–RIPK3 complex formation
por: Seong, Daehyeon, et al.
Publicado: (2020)

The Impact of RIPK1 Kinase Inhibition on Atherogenesis: A Genetic and a Pharmacological Approach
por: Puylaert, Pauline, et al.
Publicado: (2022)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016)

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
por: Martin, George
Publicado: (2023)

Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1
por: Peng, Ruoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lv0gufqf998sb5ipg65ti6bf9u